Sample Size: 125,474 adults T2DM (61.0% of total sample, n = 76,524) 98.6% (n = 75,434) using GLP-1s as antidiabetic medications 1.4% (n = 1,090) using GLP-1s as antiobesity medications Without T2DM (39.0% of total sample, n = 48,950) 61.8% (n = 30,236) using GLP-1s off-label as antidiabetic medications 38.2% (n = 18,714) using GLP-1s specifically for weight management Data Source: Truveta Data Aggregated electronic health record (EHR) data from 30 U.S
Prescription Weight Loss Drugs Risks All of these drugs can have some amount of unpleasant side effects, usually digestive
It has been approved as Mounjaro for diabetes and Zepbound for weight loss
KidgellJTMagnussonMde NysRGlassonCRK
PubMed Europe PMC Scholia The Nrf2 regulatory network provides an interface between redox and intermediary metabolism